Text/HTML

We will be performing maintenance on this site on March 24, 2024 starting at 6:00 am until 8:00 am.  We apologize for the inconvenience.  


Mobile App

Google Play Apple Store

EasyDNNNews

Advanced Clinical Cases in Reverse-remodeling Therapy: A New Era in PAH
AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Current therapies for treating pulmonary hypertension aim to overcome the imbalance between vasoactive and vasodilator mediators and restore the endothelial cell function. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of PAH. This on-demand video presentation will focus on several important aspects of PAH management, including a discussion of the challenges of diagnosing and treating patients, clinical trial data on emerging therapeutics for the management of PAH, and a review of strategies to optimize outcomes for patients with PAH.

Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.





Marc Humbert, MD, PhD Marc Humbert, MD, PhD
Professor of Medicine
University Paris-Saclay  
 Aaron Waxman, MD, PhD, FACP, FCCP Aaron Waxman, MD, PhD, FACP, FCCP
Director, Pulmonary Vascular Disease Program
Executive Director, Center for Pulmonary Heart Diseases
Brigham and Women's Hospital Heart and Vascular Center
Associate Professor of Medicine
Harvard Medical School

20

Supported by an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA


Launch Date: June 15, 2023

Release Date: May 11, 2023

Expiration Date: May 31, 2024

May 31, 2024
Mini Module
7567
TalkingPAH2022_WebBanner(1150px).gif
Pulmonology